[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-337700-105":59,"doc-detail-337700-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","the-clinical-regimens-and-cell-membrane-camouflaged-nanodrug-delivery-systems-in-hematologic-malignancies-treatment","The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment","","Hematologic malignancies pose major threats to patients by disrupting the blood, bone marrow, and lymphatic systems. Despite established clinical strategies—including chemotherapy, radiotherapy, stem cell transplantation, targeted molecular therapy, and immunotherapy—five-year overall survival remains low. Recent evidence highlights nanodrug delivery systems as a route to more precise anti-tumor effects. In particular, cell membrane camouflage can enhance targeting, reduce toxicity and side effects, and improve immune responses. This review outlines clinical regimen merits and limits, summarizes nanocarrier-based drug delivery approaches, and details cell membrane fragment functions and mechanisms that guide nanodrugs to hematologic malignancy lesions, concluding with translation and future multi-functional surface design directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/the-clinical-regimens-and-cell-membrane-camouflaged-nanodrug-delivery-systems-in-hematologic-malignancies-treatment/337700/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/the-clinical-regimens-and-cell-membrane-camouflaged-nanodrug-delivery-systems-in-hematologic-malignancies-treatment/337700.png","ImageObject",300,407,{"name":92,"@type":93},"Aurora","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-29","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":44},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why are hematologic malignancies considered high-risk for patients?","Question",{"text":112,"@type":113},"Hematologic malignancies affect the blood, bone marrow, and lymphatic systems, disrupting normal formation and function of blood cells and enabling abnormal cancer cell growth.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"Which clinical treatment strategies are commonly used for hematologic malignancies?",{"text":117,"@type":113},"Common strategies include chemotherapy, radiotherapy, stem cell transplantation, targeted molecular therapy, and immunotherapy, but overall five-year survival is still low.",{"name":119,"@type":110,"acceptedAnswer":120},"What advantages does cell membrane camouflaged nanodrug delivery offer?",{"text":121,"@type":113},"Cell membrane camouflage can enhance drug targeting, reduce toxicity and side effects, and/or improve immune response against hematologic malignancies.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},337700,1790355907,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":44,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":46,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":31,"preview_page_count":19,"preview_urls":144},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","TYPE Review  \nPUBLISHED 16 April 2024  \nDOI 10.3389/fphar.2024.1376955  \nOPEN ACCESS  \nEDITED BY  \nFeifei Yang,  \nUniversity of Jinan, China  \nREVIEWED BY  \nHao Zhang,  \nJinan University, China Ketki Bhise,  \nBiotech Industry, United States  \n*CORRESPONDENCE  \nGaofeng Liang,  \n [lgfeng990448@haust.edu.cn](lgfeng990448@haust.edu.cn)  \nRECEIVED 26 January 2024  \nACCEPTED 02 April 2024  \nPUBLISHED 16 April 2024  \nCITATION  \nLiu Y, Yu S, Chen Y, Hu Z, Fan L and Liang G (2024), The clinical regimens and cell membrane camouﬂaged nanodrug delivery  \nsystems in hematologic malignancies treatment.  \nFront. Pharmacol. 15:1376955 .  \ndoi: 10.3389/fphar.2024.1376955  \nCOPYRIGHT  \n© 2024 Liu, Yu, Chen, Hu, Fan and Liang. This isan open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nThe clinical regimens and cell membrane camouﬂaged nanodrug delivery systems in hematologic  \nmalignancies treatment  \nYuanyuan Liu 1, Shanwu Yu 2, Yixiang Chen 3, Zhihong Hu 1, Lingling Fan 1 and Gaofeng Liang 1*  \n1College of Basic Medicine and Forensic Medicine, Henan University of Science and Technology, Luoyang, Henan, China, 2College of Horticulture and Plant Protection, Henan University of Science and Technology, Luoyang, Henan, China, 3Luoyang Vocational and Technical College, Luoyang,  \nHenan, China  \nHematologic malignancies (HMs), also referred to as hematological or blood cancers, pose signiﬁcant threats to patients as they impact the blood, bone marrow, and lymphatic system. Despite signiﬁcant clinical strategies using chemotherapy, radiotherapy, stem cell transplantation, targeted molecular therapy, or immunotherapy, the ﬁve-year overall survival of patients with HMs is still low. Fortunately, recent studies demonstrate that the nanodrug delivery system holds the potential to address these challenges and foster effective antiHMs with precise treatment. In particular, cell membrane camouﬂaged nanodrug offers enhanced drug targeting, reduced toxicity and side effects, and/or improved immune response to HMs. This review ﬁrstly introduces the meritsand demerits of clinical strategies in HMs treatment, and then summarizes the types, advantages, and disadvantages of current nanocarriers helping drug delivery in HMs treatment. Furthermore, the types, functions, and mechanisms of cell membrane fragments that help nanodrugs speciﬁcally targeted to and accumulate in HM lesions are introduced in detail. Finally, suggestions are given about their clinical translation and future designs on the surface of nanodrugs with multiple functions to improve therapeutic efﬁciency for cancers.  \nKEYWORDS  \nhematologic malignancies, clinical regimens, nanocarrier, nanodrug delivery system, cell membrane camouﬂage  \n1 Introduction  \nHematologic malignancies (HMs), which are also called blood cancers, often begin in the cells of the immune system or in blood-forming tissue such as the bone marrow, where stem cells develop into blood cells, affecting the bone marrow’s ability to make enough blood cells (red blood cells, white blood cells and platelets) (Greim et al., 2014) . When abnormal HM cells grow uncontrollably, they can cause cancers to develop, outpacing the growth of healthy blood cells and disrupting their normal functions. According to the ﬁrst detected sites, the HMs are traditionally categorized as leukemias (blood), lymphomas (lymph nodes), or myelomas (bone) (Bispo et al., 2020; Alaggio et al., 2022) (Figure 1) .  \nFrontiers in Pharmacology 01 [frontiersin.org](frontiersin.org)  \nLiu et al. 10.3389/fphar.2024.1376955  \nFIGURE 1  \nSchematic of the pathological differentiation of l","cbCaikgdOHk0DDi4","https://ap.wps.com/l/cbCaikgdOHk0DDi4","pdf",2068352,"English","# Introduction\n## Leukemia\n## Lymphoma\n## Myeloma","[{\"question\":\"Why are hematologic malignancies considered high-risk for patients?\",\"answer\":\"Hematologic malignancies affect the blood, bone marrow, and lymphatic systems, disrupting normal formation and function of blood cells and enabling abnormal cancer cell growth.\"},{\"question\":\"Which clinical treatment strategies are commonly used for hematologic malignancies?\",\"answer\":\"Common strategies include chemotherapy, radiotherapy, stem cell transplantation, targeted molecular therapy, and immunotherapy, but overall five-year survival is still low.\"},{\"question\":\"What advantages does cell membrane camouflaged nanodrug delivery offer?\",\"answer\":\"Cell membrane camouflage can enhance drug targeting, reduce toxicity and side effects, and/or improve immune response against hematologic malignancies.\"}]","The clinical regimens and cell membrane camouflaged nanodrug delivery systems in hematologic malignancies treatment | PDF",1790020236,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/6071974693e73d16d0be490fd55efb89.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4dc724ffd8d268db20c1b13575f0e1f4.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8fc05ffee311c91c12a8910ea14ed0db.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f39e9f2979c6c1858412bf1214d77a57.webp",980,1385]